Lemierre's syndrome is characterized hy thrombosis of theinternaljugularv ein that developsfollowing an oropharyngeal infection. Sepsis and septi c metastasesfrequ entl y ensue and affect the lungs, the muscul osk eletal system, and occasionally the liver. Most cases are caused by infection with Fusobacterium necroph orum. This inf ection responds to antibiotic therapy with beta-lactam aseresistant compounds that exert good anaerobic cove rage . Anticoagulation and surgical interventi on can be helpful in advanced cases. Fewer than 160 cases of classic Lemierre's syndrome have been describ ed; approximately one-third of these reported cases have occurred since 1988. We describe a new case of Lemi erre 's syndrome that occurred in an othenvise health y 27 -year-old man. Thrombosis of both internaljugula I' veins extended through the subclavian system and into hoth upp er extr emities. The patient was treated with intravenous antibiotics and heparin during 14 days of hospitalization. He was discharged on oral clindamycin and warfarin sodium, and after 6months he was able to return tofull activity. To our knowledge, this is the first reported case of Lemi erre 's syndrome in which internal j ugular vein thromb osis occurred bilaterally. By reportin g this previously undescribed manifestation of Lemierre 's syndrome, we hope to increase practitioner awa reness ofthis dis ease entity.
Introduction
Internal ju gular vein thrombosis is an uncommon disease that has been associated with central intravenous catheterization, IV drug abuse , hypercoagulability, infection, and atheroscle ros is.I Virchow' s triad (stasis, endothelial injury, and hypercoagulability) promotes clot development and prop agation in the intern al j ug ular vein (as it does in any other vas cular bed), but fewer than 5% of deep venous thromb oses occur in the head and neck.' Trauma from indwe lling central venous ca theteriza tion or from the repeated use of the interna l j ugular vein by IV dru g abusers is the most co mmon ca use of intern al jugular vein thrombosis.' Thi s has not always been the cas e; during the pre-antib iotic era, intern al ju gular vein th rombosis was a common sequela to oropharyngeal infection.
In 1936 , Lemierre describ ed a syndrome that was characterized by anae robic septice mia, internal jugular vein thrombosis, and septi c emboli that aro se secondary to infections of the head and neck, particularly in the oroph arynx.' (Lemierre was not the first to describe the syndrome that bears his name, but he is accorded the eponymous honor nonetheless.) Lemi err e found that approximately 90 % of pati ent s with this illne ss had died within se veral week s of its onset. Subsequent reports of this sy ndrome-which is also known as postan ginal septicemia and a form of necrobacillosis-appeared intermittentl y in the literature until the 1950s. Most notably, Alston described 21 cases of classic Lernierr e' s syndrome in his review of28 0 cases of necrob acill osis that had been publi shed in the world literatu re between 1933 and 1955. 5 Foll owing the intro duction of antibiotics, only a small number of cases was rep orted durin g the next 30 years. In 1989, Sinave et al publi shed a thorough analysis of 38 cases that had occurred between 1974 and 1988. 6 In the same year, Eykyn co mme nted on 45 cases of necrobacillosis in England and Wales, 29 of which exhibited the clini cal characteristics of Lemi err e' s syndrome. ' Since then , only sporadic cas e reports of Lemi erre' s syndrome have app eared in the English-l anguage literature, and it came to be characterize d as a "forgotten" disea se ."
In order to raise awareness of this entity, we describe a
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Results of initial laboratory eva luations were obtained (table I) . Among the significa nt findings were a norm al leukocyte co unt, hypoalbuminemi a, normal clott ing, and elevated liver enzyme levels. Contrast-enhanced computed tom ography (CT) of the neck (figure 2) and chest (figure 3) detected thrombosis of the right jugular, distal right subcla vian, right brachioceph alic, and left ju gul ar veins. The right jugular vein clot extended from the skull base to ju st above the aortic arch. The left internal jugular vein thrombus was only partially occlusive and limited to the area of the thyroid gland. A collection of fluid and surrounding inflamm ation occupi ed the anterior midline of the neck superior to the thyroid gland. Multiple pulmonary nodules (including a ca vitary nodule in the ante rior basal seg ment of the right lower lobe), bilateral lower lobe infiltrates, and bilateral pleural effusions were also evident.
A diagnosis of Lemierre's syndrome was made, and the patient was started on IV clind amycin (900 mg q8h) and IV ceftriaxo ne (2 g q 12h). Following an initial deterioration in his respiratory status (decreased oxygen saturations and pleur itic chest pain that did not requ ire mechanical ventilation), the patient improved and began to experience less pain, swelling, and shor tness of breath. Howeve r, a ches t radiograph showe d that his pulmonary disease was persistent (figure 4). After consultations with both the infectious disease and hematology services, the patient was started on IV heparin therapy. He required twice-d aily dressing changes of the midlin e neck wound and received 14days of IV antibi otics. After discharge, he continued on oral clindamycin for 4 weeks and warfarin sodium for 6 month s. Ven ous dupl ex ultrasonography documented a gradual reduction in the size of the exten- Lumenis delivers the best choices in C02 laser solutions. so you can deliver the very best in patient care. Our systems provide the highest levels of performance and ease-of-use for applications in laryngology. otology, rhinology. and more. And. each is backed by the most extensive education and support services in the laser industry.
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Bring the latest in C02 laser technology to your OR. Contact us today to learn about our current promotional and upgrade programs: 1-800-635 -1313 or information @lumenis.com. ( 1) primary infecti on in the oropharyn x, (2) septice mia documented by at lea st one positi ve blood culture, (3) clinical or radi ographi c evide nce of intern al jugul ar vein thromb osis, and (4 ) at least one metastatic focus." We determined that 40 of the 54 cases that wer e described by others since the publ ication of the report by Sinave et al were docum ent ed to have met all four crit eria, and these are the case s that we discu ss in this article, in addition to our ow n case (table 2) . Altho ugh the clinical criteria for Lemierre ' s syndro me might have been met in the other 14 cases ,":" we did not include them in this rev iew because there was either an absence of document ed metastatic foci , abse nt or negative blood cultures, undocument ed interna lj ug ular vein thrombosis , or a primary infec tion that arose either outside the oroph arynx or as a seq uela to trauma.
Two Leaders-Now One Powerful Source
Moreover, an oth er 29 patient s were described in two series that exa mined necrobacillosis and septic interna l ju gular vein thromb osis, but ins ufficient data preclude these patients fro m co nsideration in thi s study. 23.24 As was the case in the revi ew by Sinave Oth er sites of septic emboli or direct extension of thromb osis included the liver ,":" :" long bon e and extr emity joints,25.32.34.36 the glutea l region,9.4 6 . 47 the sternum," and the crani al vault." Pat ient s also experienced systemic manifestation s of illness , such as derangement s of liver Is your patie to tell you so • ttylng ething?
Dry mouth due to radiation-induced xerostomia is not only uncomfortable, it can lead to oral health complications. 1 With the longest record of clinically proven efficacy and time proven safety of any prescription dry mouth treatment , Salagen Tablets can restore patients ' natural protective saliva. Use of Salagen Tablets is supported by:
• More than 23,000,000 patient-days of therapy'
• Consistent, statistically significant improvements Inaddition, thefollowingadverseevents (~3 ' 10 incidence) werereported at dosages of 15-30mg/day in the controlled clinical trials: Headache(11%), dyspepsia (7%), lacrimation (6%), edema (5%), abdominal pain (4%), amblyopia (4%), vomiting (4%) , pharyngitis (3%),hypert ensi on (3%).
The following eventswere report edwith treated head and neck cancer patient s at incidences of 1% to 2% at dosages of 7.5 to 30 mg/day: abnor mal vision, conjunctivitis, dysphagia, epistaxis, myalgias, pruritus, rash, sinusitis, tachycardia, taste perversi on, tremor,voicealteration.
The fol/owing events were reporfed rarely in treated head and neck cancerpatienls (<1%): Causal rel ation is unknown.
Body odor , hypothermia, mucous membrane abnormal ity, bradycardia, ECG abnormality, palpitations, syncope, anorexia, increased appetite, esophagit is, gastrointestinal disorder, tongue disorder , leukopenia, lymphadenopathy, anxiety, confusi on, depression, abnormal dreams, hyperkinesia, hypoesthesia, nervousness, paresthesias, speech di sorder, twi tching,increasedsputum,stri dor, yawning,seborrhea, deat ness, eyepain, glaucoma, dysu ri a, metrorrhagi a, urinary impairment.
In long-term treatment were two patients withunderlying cardiovascular di sease of whom one experienced a myocardial infarct and another an episodeof syncope. The association with drugis uncert ain.
Sjogren'sSyndromePatients: Incontrolled studies,376 patients received pi locarpine, of whom 5% were men and 95% were wome n. Race distribution was 84% Caucasian, 9% Oriental , 3% Black, and 4% ofother origin. Mean age was 55 years. The major ity of patient s were between 40 and 69 years (70%), 16% were 70 years and older and 14% were younger than40yearsof age. Ofthesepatients, 161/629 (89/376 receiving pilocarpine)wereovertheageof65years.Theadverseeventsreported by those over 65 years and those 65 years and younger werecomparable except tor notable trends forurinary frequency, diarrhea, and dizzine ss. The incidences of urinary frequency and diarrhea in the el derly were about doublethoseinthenon-el derly.The incidenceof dizzinesswasabout three times ashigh in theelderly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebo- Pilocarpine may increase ureteral smooth muscle tone and could theoretically precipitate renat colic (or "ureteral reflux"), part icularly in patientswilh nephroli thiasi s.
Cholinergic agonists may have dose-related central nervous system effects. This shouldbeconsideredwhen treating patientswith underlyi ng cognitive or psychi atricdisturbances.
Renat Insuffici ency: The pharmacokinetics of orally administered pilocarpine in patients with renal and hepatic disease is not known.
Information for Patient s:
Patients should be informed that pilocarpi ne may causevisual disturbances, especiallyat ni ght, that could impair their abilityto drivesafely.
If a patient sweats excessively while taking pilocarpi nehydrochi oride and cannot drink enough liquid, the patient should consul t a physi cian. Oehydrati onmay develop.
Orug Interactions: Pilocarpine shoutd be administered with caution to patients taking beta adrenergic antagonists because of the possi bility of cond uction disturbances. Or ugs with parasympathomi metic effects administeredconcurrent lywith pilocarpine wouldbeexpected to result in additive pharmacologic effects . Pitocarpine might antagonize the anticholi nergic effects of drugs usedconcomitantly. These effects sho uld be considered when anticholinergic properties may be contributing to the therapeutic effect of conco mitant medication(e.g., atropine, inhaled ipratropium).
While no formal drug interaction studies have been performed, the followi ngconcomitant drugs were used in at least 10%of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estro gens, hydroxychloroquine sulfate, ibuprof en, levothyroxine sodium, medroxyprogesterone acetate, methot rexate, multivitamins, naproxen, om eprazole, paracetarnol.andprednisone.
Carcinogenesis, Mutagenesis, Impairment of Fertility: No defi nitive
long term animal studies have evaluated the carcinogenic potential of pilocarpine, No evidence that pilocarpine hasthe potential to causegenetic toxicity was obt ained in a series of studies that included: 1) bacterial assays (Salmonellaand E. coli) for reversegene mutations; 2) an in vitro chromosome aberrati on assay in a Chinese hamster ovarycell line; 3)an in vivo chromosome aberration ass ay (micronucleustest) in mi ce; and 4) a primary DNA damage assay (unscheduted DNA synthesis) in rat hepatocyt e primarycullures.
Oral administ ration of pilocarpine to male and female rats al a dosage of 18 mg/kg/day (approxi mately 5 times the maximum recommended dose for a 50 kg human when compared on the basis of body surface area (mg/m) estimates ) resulted in impairedreproductive function, including reduced fertitity, decreased sperm motility,and morphol ogic evidence ot abnormal sperm.It is unclear whether thereductionin fert ility was due to effects on mat e animals,female animals, or both males and females. 
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controlled studies, the mostcommon adverse eventsrelated todrug use were sweating, uri nary frequency, chills, andvasodilatation (llushing). The most com monly reported reason forpati ent discontinuation of treatment wassweating. Expectedpharmacol ogic effects of pitocarpine incl ude the followingadverse experiences ass ociated with SALAGEN' Tabtets: Inaddition, thefollowing adverse events",3%incidence) were report ed at dosing of 20 mglday in the controlled clinical trial s: Headache (13%), lIu syndrome (9%), dyspepsia (7%), dizziness (6%), pain (4%) , sinusitis (4%),abdominal pain (3%), pharyngitis (2%), rash (2%), infection (2%).
The foll owing events were reported in Sjogren's patients at incidences of 1% to 2%at dosingot 20 mglday: accidental injury, allergicreaction, back pai n, blurredvision, constipation, increasedcough, edema, epistaxis, face edema, fever, flatul ence, glossitis, lab test abn ormalities including chemistry, hematology, and urinalysis, myalgia, palpitation, pruritus, somnolence, stoma titis, tachycardia, tinnitus, urinary incontinence, urinary tract infection, vaginitis, vomi ting.
The tollowingadverse experiences have beenreported rarely with ocular pi locarpine: A-V block, agi tation, ciliary congestion, confusion, del usion, depression,der matitis,middleear disturbance, eyelid twitchi ng, malignant gtaucoma,iris cysts, macul ar hol e, shock, and visual hall ucination.
MANAGEMENT OF OVEROOSE: Fatal overdosage with pilocarpine has been report edin the scientitic literature at doses presumedto begreal er than 100 mg in two hospi talized pat ients. 100 mg of pilocarpi ne is considered potentiall y fatal.Overdosage shoul d be treated with atropine titration (0.5 mg to 1.0 mg given SUbcutaneously or intravenously) and supportive measures to maintainrespiration and circulat ion. Epin ephrine (0.3 mg to 1.0 mg, subcutaneously or intramuscul arly) may also be of value in the presence of severe cardiovascular depression or bronchoconstricti on. II is notknown if pi locarpine is dial yzabl e.
OOSAGE ANO AOMINtSTRATlON:
Head& Neck Cancer Pati ents:
The recommended initial dose ot SALAGEN' Tablets is one tablet (5 mg) taken three times a day, Dosage should be titrated according to therapeutic response and tol erance. The usual dosage range is up to 3-6 tablets or 15-30 mg perday. (Notto exceed 2 tabl ets per dose.) Although early improvement may be realized, at least 12 weeks of uninterrupted therapy with SALAGEN" Tabl ets may be necessaryto assess whether a beneficial response will beachieved.The incidence ot themost common adverse events increases with dose. The lowest dose that is tol eratedand effective should be used for mai ntenance.
Sjogren's Syndrome Palients:
The recommendeddose of SALAGEN' Tabtets is one tablet (5 mg and regim en are unavailable for two of these patients." :" Eleven patient s (26.8 %) required anticoagulation over a period of I week to 6 months. Th irty-nine of the 41 patient s (95 .1%) survived; of the two who did not, one died from fulmin ant pneum oni a and the other from seve re sepsis. 28 ,46 ,p Our analysis revealed that there are striking similarities betw een our 41 cases and the cases of Lemierre' s syndrome that were reported from 1974 throu gh 1988 by Sinave et al with respect to patient dem ographics, sites of meta stat ic invol vement, types of pathogen , treatm ent modaliti es, and outcomes ."
Discussion
We rep ort the first case of bilateral interna l ju gular vein thromb osis in a pati ent with Lernierre' s syndrome. Wh en Lem ierre first described the syndrome of postan ginal sepsis, he noted that most cases develop ed in the setting of oro pharyngea l infec tion." Furtherm ore , he ackno wledge d that intern al ju gular vein thrombophl ebitis could exhibit manifestations in the ear, masto id, and sinuses, as well. ' Clinical features. Lemierre' s syndrome is cha racterized by thrombosis of the internal ju gular vein that develops following oro pharyngea l infection. Sep sis and septic metastases frequently ensue, and they can affect the lungs, the musculoskeletal system, and on occasion the liver. Pharyngiti s, tonsilliti s, or gingivitis accounts for the initi al infection and fever, which are typically foll ow ed in I to 3 weeks by the development of neck pain and swelling , respi rator y decompensation , or myalgias and arth ralgias. This pattern of event s is fairly pathognomonic; in fact, Lemierre noted that this syndrome is so ch aracteristic that "mistake is alm ost impossible.?' Even so, delays in diagnosis are common. The incidence of Lemierre' s syndrome and associ ated mort ality hav e decreased substanti ally since the dawn of the antibiotic age ." In fact, only two death s have been document ed since 1990. 28 .46 Nevertheless, prolonged morbidity (and its attendant financi al and social costs) can persist, as it did in our patient.
Although Streptococcus, Bacteroides, and Lactobacillus spp. as well as other Fusobacter ium spp. have been implicated in the pathogenesis of Lemi erre' s syndro me, F necrophorum is the most comm on patho gen isolated from blood cultures in these patient s. The Fusobac terium organism is a normal component of the flora of the oral cavity, and it exists in large numb ers in the gingival crevice and the subgingival plaque of adult s. This genus also resides in the large bowel and in the female genital tract. An anaerobic, gram-nega tive bacillu s, F necroph orum can be filamentous or fusiform in appearance." In addition to orop haryngea l infections, Fuso bacterium spp. have been implicated in the development of endocarditi s, soft-tissue infections, and brain , hepat ic, and intra-abdominal abscesses. Fusobacterium spp. have been assoc iated with as many as 46 % of all head and neck infections, frequently in conjunction with other organisms."
A disruption of normal host muc osal defenses throu gh trauma or hypoxi a can provide a supportive environ ment for the proli feration of these bacte ria." Bacteri al produ ction of proteolytic enzymes, lipopolysaccharide endotoxin, leukocidin, and hemagglutinin account s for the pathogenicity of F necroph orum, which then invade the regional veins." The hemagglutinin moiety has been shown to aggregate bovine platelets, which might account for the intern al ju gular vein thrombosis of Lemierre ' s syndrome."
The nomencl atur e of this class of bacteria has undergone significant evolution over the past 50 years. The current classification is based on selec tive culturin g technique s and analysis offatty-acid end product s. Alth ough 240 Figure 5 . Duplex ultrasonography of the right axillary vein demonstrates a persis tent but slight thrombosis after ti months of anticoagulation. This fi nding represents a dramatic improvement in our patient 's condition.
other anaerobic bacilli such as Bacteroides spp. can be invol ved in oroph aryngeal infection s, Fusobacterium spp. can be differentiated by their produ ction of n-butyric acid alone."
The oropharynx-particularly the palatine tonsilsprovides the source of infection in most cases of Lernierr e' s syndrome. The anatomy of the lateral pharyngeal space promot es invasion of the intern al ju gul ar vein in the retro styloid comp artment. An inverted cone extending from the skull base to the hyoid, the lateral pha ryngeal space is bounded medially by the superior pharyn geal constrictor and laterally by the medial pte rygoid. The styloid process divides this anatom ic space into anterior and posterior comp artments; the contents of the carotid sheath and cranial nerv es IX through XII reside in the posterior comp artm ent. Ton sillar infection can involve the ju gular vein by direct extension throu gh this fascial space or by hemat ogenou s or lymph atic spread from peritonsillar vesse ls."
After the development of internal ju gul ar vein thrombosis, septic emb oli can emerge and affect distant sites. Num erou s reports of pulmo nary involve ment-ranging from discrete nodularity to emp yema thora cis and adult respiratory distress syndrome-have been published. • Without fragrance or unpleasant taste
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Adverse eventsoccu rringatan inci denc e of 2% or greater and more common amongadult patients treated wit h pl acebo than Nasacort AQ were: headache. and rhinitis. Inchildrenaged 6 to12 yearsthese eventsincl uded: asthma. epistaxis, headache,infection, otitis media, sinusitis, andvomiting. In clin ica l trials, nasal septum perforation was report ed in oneadult patient although relationship to Nasacort AQ NasalSprayhas not beenestablished. 
PADDOCK ORAL POWDERS
Nystatin USP
For Extemporaneous Preparation of Oral Suspension
Have your patients swish-and-swallow the sensible sugar-free way
Large oral doses occassionally produced diarrhea, GI distress, and possible irritation of the stomach that may cause nausea and vomiting. CH, ration, pleuriti c chest pain , or hemoptysis. Liver abscesses can occur, but elevations in both intra-and extracellular liver enzyme level s appear to be more common,9. 10 as was evident in our patient. The long bones can be affec ted by osteomyeliti s, and joi nts such as the elbo w, knee, and ankle can also be affected. 25.32.34,36 Soft-tissue abscesses have also been described, and they often required dr ain age before sys temic imp rov em ent was noted . 9 . 34 ,46,47 Multiple hematologic abnormalities have been report ed, inclu ding thromb ocytopenia and disseminated intravascular coag ulation.v'v" Neurol ogic and intracranial complications such as meningitis and cranial nerve palsies can even OCCUr. 48 The myriad manifestations of Lemierre' s syndrome often complicate its diagnosis and cause a delay in appropriate therapy. Evaluation of the patient with suspected Lemierre's syndrome should begin with a thoro ugh history and physical examination , because abnormalities can be present in more than one organ system.
Chest radiography is indicated when pulm onary symptoms are present, and appropriate laboratory studiesincluding measurements of the complete blood count and electrolyte and liver enzyme levels-can provide insight into the extent of disease. Blood culture results, both aerobic and anaerobi c, should be obtained prior to initiating antibiotic therapy.
Imaging studies. Radi ographic evaluation of the neck and internal jugular veins can be accompli shed in several ways: via venou s duplex ultrasonography, CT with IV contrast (in patients with adequate renal function), magnetic resonance imaging (MRI ), magnetic resonance venogra phy, nuclear scintigraphy, and gallium-67 scanning.
Although contras t venography is the gold standard, the attendant radiation expo sure, invasivene ss, and risk of perforation or embolic events might outweigh its utility. Venous duple x ultra sono graphy is accurate and provides reproducible detection of intralum inal thrombosis or abscess, but its/application can be limited by the anatomic ! location of-the clavicle and mandibl e, as well as variability in the skill level of the technici an. Although acute thrombus can be missed because of its low degree of echogenicity, thromb osed veins are typically dilated and incompressible, and they feature either a lack of venous pul sations or a flow that does not vary durin g sniffing or Valsalva' s maneuver." Venous duplex ultr asonography is an inexpensive method of documenti ng imp rovement or resolution of thrombo sis ( figure 5) .
The most common modality employed to diagnose intern al j ugular vein thrombosis is CT with IV contra st." Radiographically, the internal ju gular vein will be dilated and there will be a low-attenu ation intralum inal content and enhancement of the vesse l wall and surrounding tissue. The wall enhancement has been attributed to the uptake of the contrast material by the vasa vasorum. It is known to be a mixture, b e composition has not been completely elucidated. NystatinA is closely relatedto amphotericin B. Eachis a macrocyclic lactone containinga ketal ring, an all-trans polyenesystem, and a mycosamine (3-amino-3-deoxy-rhamnose) moiety. NystatinAhas a molecul arformula of C47H7SN017 and a molecular weight of 926.11.
OH
Nystatin A Nystatin USP is a ready-to-use, non-steril e powder for oral administration which contains no excipients or preservatives. It is available in containers of 50 milli on, 150 milli on, 500million, and 2 billi onunit s. Each mgcontai nsa minimum of 5,000 units.
CLINICAL PHARMACOLOGY
Nystatin probably acts by binding to sterols in the cell membrane of the fungus with a resultantchange in membrane permeabilityallowing leakage of intracellular components. It is absorbed very sparinglyfoll owing oral administration, with no detectable blood levels when givenin the recommended doses. Most of the orally administered nystatinis passed unchangedin thestool.
INDICATIONS FOR USAGE
For the treatment of intestinal and oral cavity infections caused by Candida (Monilia) albicans.
CONTRAINDICATIONS
Hypersensitivity to the drug.
ADVERSE REACTIONS
Large oral doses of nystatinhave occasionallyproduced diarrhea, gastrointestinal distress, and possible irritation of the stomach that may resultin nausea and vomi ting.
DOSAGE AND ADMINISTRATION General
Adults and older children: Add 1/8 teaspoonful (approximately 500,000 uni ts) of Nystatin USP to about 1/2 cup of water and stir well. One-eighth teaspoonful of Nystatin USP is equivalent to the recommended dose for adults and children of Nystatin Or al Suspension (4 to 6 mL, or 400,000 to 600,000 units). This product contains no preservat ives and therefore should be usedimmediatelyafter mi xing and should not be stored. It is designed for extemporaneous preparation of a single dose at a time. Infections of the oral cavity caused by Candida (Monilia) albicans: Infant s: 200,000 unit s four times dail y. Children and adults: 400,000 to 600,000 unit s fourtimes daily (one-halt dose in each side of mouth).
NOTE: Limited clinical studies in premature and [ow birth-weight infant s indi cate that 100,000 units fourtimes daily is effective. Local treatment should be continued at least 48 hours after peri oral symptoms have disappeared and cultures returned to normal.
It is recommended that the drug be retained in the mouth as long as possibl e before swallowi ng. Intestinalcandidiasis (moniliasis) Usualdosage: 500,000to 1 millionunits (approximately 1/8 to 1/4 teaspoonful ) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse. HOW SUPPLIED Nystatin USP is supplied in containers of 50 million, 150 milli on, 500 million, and 2 billi onunits. y BILATERAL LEMJERRE'S SYNDRO ME: A C ASE REPORT AN D LITERATURE REVIEW Although CT does involve radia tion expos ure and the administrat ion of intravenous con trast, it is rapi d and reliable."
MRI provides an exce llent delineation of soft tissues wit ho ut rad iation exposure and with the benefit of mult iplanar viewing. Some authors attest that magnetic resonance venography is the most accurate and reliable method of detecting the presence and exte nsion venous throm bosis, and its correlation to contras t venog raphy has been reported to be as high as 97%.12 Neither nucl ear scintigraphy nor gallium-67 scanning approa ches the reliability and ease of CT, MRI , or magnetic reson ance venography .P-"
Treatment. Antibiotic therapy-particularly with a betalactamase-resistant comp ound that provides excellent anaero bic coverage-is the mainstay of treatment. Metronidazole, penicillin, and clindamycin are the most frequentl y used drug therapies. However, the emerge nce of beta-lactamase-produc ing strains can minimize the efficacy of penicillin. Therefore, beta-Iactamase-resistant antibiotics are becomin g more popul ar because they typically overcome this type of bacterial resistance." Dependin g on the severity of the infection, antibiotics should be administered intr avenously for 7 to 14 days, followe d by an additional 2 to 4 weeks of oral antibio tics. 10 The use of additional measures-such as surgical drainage of abscesses, ligation of thrombosed vessels, and administration of an anticoagulant-depends on both the severity of the illness and its response to antibiotic treatment. Surgical interventi on is indicated if there is a lack of impro vement after 48 to 72 hours of intravenous antibiotic therapy, a worsenin g of systemic illne ss, or the development of sepsis. Our patient likely benefited from the incision and drainage of his midline neck mass, which was initially presumed to be a thyroglossal duct cyst. Other authors have docum ent ed improvement following surgical intervention.lv"
The fact that 11 ofthe 41 patients (26.8 %) in this review impro ved following the addition of anticoag ulation therapy supports its use in cases of extensive thrombosis . 8.12.25.32.33.44.48 In conclusion, Lemierre' s syndrome is less common now than it was during the pre-antibiotic era, but it remains a serious entity. It carries significant morb idity and a low but co nsistent risk of mortality. Despite intermitten t reports of this illness, delays in diagnosis continue to occ ur. It is our hope that this article will increase aware ness of this rare clinical entity and min imize diagnostic and therapeutic delay.
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